Overview

A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma

Status:
Completed

Trial end date:
2017-08-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate improvement of peripheral airway resistance (R5-R20) from baseline with fluticasone/formoterol breath actuated inhaler (BAI).

Phase:

Phase 3

Details

Lead Sponsor:

Mundipharma Research Limited

Treatments:

Fluticasone
Formoterol Fumarate
Xhance